comparemela.com

Latest Breaking News On - Specialized drugs - Page 6 : comparemela.com

FDA Extends Review of Rocket Pharma s Proposed Kresladi

By Colin Kellaher Rocket Pharmaceuticals on Tuesday said the U.S. Food and Drug Administration has extended its review of the biotechnology company's.

Colin kellaherDrug administrationRocket pharmaceuticals onArticle normalHealthcare life sciencesAerospace defenseSpecialized drugs medicationsIndustrial goodsRegulation government policyNew products servicesProduct service approvalsCorporate industrial newsProducts servicesContent typesFactiva filtersC amp ampe industry news filter

Biogen stock slides as quarterly results fall short of expectations

Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining.

Chris viehbacherEisai coEli lilly coBiogen incWall streetEli lillyArticle normalAgricultural machineryCommercial bankingHealthcare life sciencesBanking creditSpecialized drugs medicationsFinancial servicesIndustrial goodsNeurodegenerative disease drugsFinancial performance

Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA s Supplemental NDA Approval

By Sabela Ojea Merrimack Pharmaceuticals said it will receive a $225 million milestone payment from Ipsen after the U.S. Food and Drug Administration.

Sabela ojeaMerrimack pharmaceuticalsDrug administrationArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsRegulation government policyNew products servicesProduct service approvalsCorporate industrial newsProducts servicesContent typesFactiva filtersC amp ampe industry news filterGovernment policy

Merrimack Pharmaceuticals to Hold Meeting on Corporate Dissolution

By Denny Jacob Merrimack Pharmaceuticals plans to hold a special shareholder meeting to approve a plan for a corporate dissolution. The biopharmaceutical.

Denny jacobDrug administrationMerrimack pharmaceuticalsArticle normalCancer drugsHealthcare life sciencesSpecialized drugs medicationsRegulation government policyNew products servicesProduct service approvalsCorporate industrial newsProducts servicesContent typesFactiva filtersC amp ampe industry news filterIpn fr

CSL Says Cardiovascular Drug CSL112 Didn t Meet Efficacy Endpoint After Study

By Mike Cherney SYDNEY Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular.

New south walesMike cherneyArticle normalBiotechnology servicesCardiovascular drugsHealthcare life sciencesSpecialized drugs medicationsNew products servicesResearch developmentCorporate industrial newsProducts servicesNew product service testingCardiovascular conditionsPolitical general newsMedical conditionsContent types

vimarsana © 2020. All Rights Reserved.